Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced

Dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) and cdc2-like kinases (CLKs) are implicated in the onset and progression of Down syndrome (DS) and Alzheimer’s disease (AD). DYRK1A has emerged as a possible link between amyloid-β (Aβ) and Tau, the major pathological proteins in AD. We here assessed the neuroprotective potential of a novel inhibitor of DYRKs/CLKs. The Leucettine L41, acting preferentially on DYRK1A, was tested in Aβ25–35treated mice, a nontransgenic model of AD-like toxicity. We co-injected intracerebroventricularly oligomeric Aβ25–35 peptide and L41 in Swiss male mice. After 7 days, they were submitted to behavioral tests addressing spatial and non-spatial, short- and long-term memories. The oxidative stress, apoptotic markers, kinases involved in Tau phosphorylation, and synaptic integrity were analyzed by Western blot and ELISA in the hippocampus. L41, tested at 0.4, 1.2, 4 mg, prevented the Aβ25–35-induced memory deficits in the Y-maze, passive avoidance and water-maze tests, with the most active dose being 4 mg. The inhibitor prevented the Aβ25–35induced oxidative stress, as revealed by measures of lipid peroxidation levels and reactive oxygen species accumulation, and abolished Aβ25–35-induced expression of pro-apoptotic markers. L41 prevented the Aβ25–35-induced decrease of AKTactivation and increase of glycogen

[1]  K. Iqbal,et al.  Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease , 2014, Expert opinion on therapeutic targets.

[2]  L. Meijer,et al.  Chemical synthesis and biological validation of immobilized protein kinase inhibitory Leucettines. , 2013, European journal of medicinal chemistry.

[3]  M. Castelo‐Branco,et al.  Triplication of DYRK1A causes retinal structural and functional alterations in Down syndrome. , 2013, Human molecular genetics.

[4]  S. H. Kim,et al.  Blockade of Tau Hyperphosphorylation and Aβ1–42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer’s Disease , 2013, Neuropsychopharmacology.

[5]  S. Marchal,et al.  Alzheimer's Disease Related Markers, Cellular Toxicity and Behavioral Deficits Induced Six Weeks after Oligomeric Amyloid-β Peptide Injection in Rats , 2013, PloS one.

[6]  J. Satayavivad,et al.  Pharmacological inhibition of GSK3 attenuates DNA damage-induced apoptosis via reduction of p53 mitochondrial translocation and Bax oligomerization in neuroblastoma SH-SY5Y CELLS , 2012, Cellular & Molecular Biology Letters.

[7]  G. Paxinos,et al.  Paxinos and Franklin's the Mouse Brain in Stereotaxic Coordinates , 2012 .

[8]  L. Meijer,et al.  Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. , 2012, Journal of medicinal chemistry.

[9]  M. Smith,et al.  Inhibition of Bax protects neuronal cells from oligomeric Aβ neurotoxicity , 2012, Cell Death and Disease.

[10]  Amy Slender,et al.  Altered regulation of tau phosphorylation in a mouse model of down syndrome aging , 2012, Neurobiology of Aging.

[11]  E. Klann,et al.  Amyloid β: linking synaptic plasticity failure to memory disruption in Alzheimer’s disease , 2012, Journal of neurochemistry.

[12]  S. Marchal,et al.  Time-course and regional analyses of the physiopathological changes induced after cerebral injection of an amyloid β fragment in rats. , 2011, The American journal of pathology.

[13]  L. Meijer,et al.  Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. , 2011, Journal of medicinal chemistry.

[14]  Jerzy Wegiel,et al.  Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A). , 2011, Archives of biochemistry and biophysics.

[15]  K. Chung,et al.  Dyrk1A Positively Stimulates ASK1-JNK Signaling Pathway during Apoptotic Cell Death , 2011, Experimental neurobiology.

[16]  Sun-Young Lee,et al.  Dyrk1A‐mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimer’s disease , 2010, Journal of neurochemistry.

[17]  G. Réus,et al.  Harmine and Imipramine Promote Antioxidant Activities in Prefrontal Cortex and Hippocampus , 2010, Oxidative medicine and cellular longevity.

[18]  E. Kosenko,et al.  Subcellular and metabolic examination of amyloid-β peptides in Alzheimer disease pathogenesis: Evidence for Aβ25–35 , 2010, Experimental Neurology.

[19]  M. Staufenbiel,et al.  Independent effects of intra- and extracellular Abeta on learning-related gene expression. , 2009, The American journal of pathology.

[20]  G. Cole,et al.  GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals , 2009, Neurobiology of Disease.

[21]  J. Wegiel,et al.  Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  Hyun-Jeong Cho,et al.  Dual‐specificity tyrosine(Y)‐phosphorylation regulated kinase 1A‐mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer’s disease , 2008, Journal of neurochemistry.

[23]  A. VanDongen,et al.  Arc/Arg3.1 Translation Is Controlled by Convergent N-Methyl-D-aspartate and Gs-coupled Receptor Signaling Pathways* , 2008, Journal of Biological Chemistry.

[24]  木村 亮.  The DYRK1A gene, encoded in chromosome 21 down syndrome critical region, bridges between β-amyloid production and tau phosphorylation in Alzheimer disease , 2007 .

[25]  I. Ferrer,et al.  Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models , 2005, Neurobiology of Disease.

[26]  G. Pigino,et al.  A novel CDK5‐dependent pathway for regulating GSK3 activity and kinesin‐driven motility in neurons , 2004, The EMBO journal.

[27]  F. Liu,et al.  Divergent roles of GSK3 and CDK5 in APP processing. , 2003, Biochemical and biophysical research communications.

[28]  J. Guzowski,et al.  Amyloid suppresses induction of genes critical for memory consolidation in APP + PS1 transgenic mice , 2003, Journal of neurochemistry.

[29]  T. Foster,et al.  Gene Microarrays in Hippocampal Aging: Statistical Profiling Identifies Novel Processes Correlated with Cognitive Impairment , 2003, The Journal of Neuroscience.

[30]  D. Selkoe.  Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[31]  K. Lau,et al.  Cyclin-Dependent Kinase-5/p35 Phosphorylates Presenilin 1 to Regulate Carboxy-Terminal Fragment Stability , 2002, Molecular and Cellular Neuroscience.

[32]  Philip R. Cohen,et al.  The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. , 2001, The Biochemical journal.

[33]  R. Tanzi,et al.  GSK3β Forms a Tetrameric Complex with Endogenous PS1‐CTF/NTF and β‐Catenin: Effects of the D257/D385A and FAD‐linked Mutations , 2000 .

[34]  D. Flaherty,et al.  Phosphorylation of human tau protein by microtubule‐associated kinases: GSK3β and cdk5 are key participants , 2000, Journal of neuroscience research.

[35]  G. Mills,et al.  Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[36]  P. Greengard,et al.  Neuron‐Specific Phosphorylation of Alzheimer's β‐Amyloid Precursor Protein by Cyclin‐Dependent Kinase 5 , 2000, Journal of neurochemistry.

[37]  David S. Park,et al.  E2F1 Mediates Death of B-amyloid-treated Cortical Neurons in a Manner Independent of p53 and Dependent on Bax and Caspase 3* , 2000, The Journal of Biological Chemistry.

[38]  P. Worley,et al.  Homer Regulates the Association of Group 1 Metabotropic Glutamate Receptors with Multivalent Complexes of Homer-Related, Synaptic Proteins , 1998, Neuron.

[39]  A. Takashima,et al.  Activation of tau protein kinase I/glycogen synthase kinase-3β by amyloid β peptide (25–35) enhances phosphorylation of tau in hippocampal neurons , 1998, Neuroscience Research.

[40]  I. Grundke‐Iqbal,et al.  Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5 , 1997, Molecular and Cellular Biochemistry.

[41]  T. Glover,et al.  Isolation of human and murine homologues of the Drosophila minibrain gene: human homologue maps to 21q22.2 in the Down syndrome "critical region". , 1996, Genomics.

[42]  N. Shimizu,et al.  Cloning of a human homolog of the Drosophila minibrain/rat Dyrk gene from "the Down syndrome critical region" of chromosome 21. , 1996, Biochemical and biophysical research communications.

[43]  A. Aplin,et al.  In Vitro Phosphorylation of the Cytoplasmic Domain of the Amyloid Precursor Protein by Glycogen Synthase Kinase‐3β , 1996, Journal of neurochemistry.

[44]  A. Privat,et al.  Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction , 1996, Brain Research.

[45]  T. Haley,et al.  Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. , 1957, British journal of pharmacology and chemotherapy.

[46]  M. Dierssen,et al.  Therapeutic approaches in the improvement of cognitive performance in Down syndrome: past, present, and future. , 2012, Progress in brain research.

[47]  S. Mandel,et al.  Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG). , 2008, Journal of Alzheimer's disease : JAD.

[48]  T. Uema,et al.  The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. , 2007, Human molecular genetics.

[49]  R. Malenka,et al.  AMPA receptor trafficking and synaptic plasticity. , 2002, Annual review of neuroscience.

[50]  J. Garrido,et al.  Molecular Neuroscience Review Article Modulation of Gsk-3 as a Therapeutic Strategy on Tau Pathologies Role and Regulation of Gsk-3 Activity , 2022 .